June 5, 2013 | Adaptive trials continue to gain ground, says Ken Getz, Director of the Tufts Center for the Study of Drug Development. He says the industry as a whole is seeing an adoption rate of about 20%, with regulators receptive to even broader implementation. Outsourcing Pharma